Table 4.
The Ocular Presentations in Patients with Retinal Vessel Occlusion after SARS-CoV-2 Vaccination
| BNT162b2 | mRNA-1273 | P Value | Chi-square | |
|---|---|---|---|---|
| Ocular presentations | ||||
| Macular edema | 116 (12.47%) | 18 (7.96%) | 0.0737 | 3.1968 |
| Retinal vasculitis | 24 (2.58%) | 2 (0.88%) | 0.1958 | 1.6738 |
| Retinal hemorrhages | 45 (4.84%) | 8 (3.54%) | 0.5073 | 0.4395 |
| Cilioretinal artery occlusion | 8 (0.86%) | 0 | 0.3407 | 0.90775 |
| Cotton wool spots | 3 (0.32%) | 0 | 0.8991 | 0.01607 |
| Retinal detachment | 9 (0.97%) | 1 (0.44%) | 0.7146 | 0.1336 |
| Papilledema | 5 (0.54%) | 3 (1.33%) | 0.4032 | 0.6986 |
| Medications | ||||
| Steroids | 10 (1.08%) | 3 (1.33%) | 1 | < 0.0001 |
| Insulin | 10 (1.08%) | 2 (0.88%) | 1 | < 0.0001 |
| Anticoagulants | 92 (11.26%) | 1 (0.44%) | 0.0014 | 10.146 |
| Aspirin | 35 (3.76%) | 7 (3.10%) | 0.776 | 0.0809 |
| Statins | 71 (7.63%) | 5 (2.21%) | 0.005 | 7.858 |
SARS-CoV-2 = severe acute respiratory syndrome coronavirus.